ADT Combinations With Radiation for Prostate Cancer: A Systematic Review and Meta-analysis
Abstract
Purpose: There is substantially heterogeneous use of luteinizing hormone-releasing hormone analogs (LHRHa) with or without first-generation nonsteroidal antiandrogens (NSAA, eg, bicalutamide) during radiation for localized prostate cancer. The primary objectives of this study were to determine the impact of NSAA on overall survival (OS), other-cause mortality, and toxicity.
Methods and materials: We performed a systematic search of studies conducted between 1966 and March 2026 evaluating androgen deprivation therapy (ADT) duration, with or without NSAA, when combined with definitive or salvage radiation therapy for localized prostate cancer. Trials including second-generation NSAA, surgical castration, lifelong ADT, or intermittent ADT were excluded. PRISMA guidelines were used for abstracting data and assessing data quality and validity, with independent extraction by 2 observers. Data were pooled using a random-effects model.
Results: Although prolonging LHRHa duration was associated with improved OS, prolonging NSAA was not (ref 1-2 months; 3-5-month NSAA hazard ratio, 1.54, 95% CI, 0.97-2.44, P = .07; ≥6-month NSAA hazard ratio, 1.68, 95% CI, 1.07-2.63, P = .02). Longer durations of NSAA or LHRHa were not significantly associated with other-cause mortality. Prolonging NSAA duration was associated with higher odds of early ADT discontinuation (ref 0-2-month NSAA; 3-5-month odds ratio, 5.05, 95% CI, 1.21-21.16, P = .03; 6-9 months, 3.97, 95% CI, 0.94-16.67, P = .06),…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.